📰 Peter Lebowitz News

Page 3 - Peter Lebowitz News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Peter Lebowitz. Real-time updates on events, politics, business and more.

Janssen Submits Supplemental Biologics License Application to U.S. FDA Seeking Approval of CARVYKTI® for the Earlier Treatment of Patients with Relapsed or Refractory Multiple Myeloma

June 6, 2023

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a supplemental Biologics License Application (sBLA)...

United States Hemophagocytic Lymphohistiocytosis Satu Glawe Peter Lebowitz Obrian Kenney Data Monitoring Committee

Source: prnewswire.com

Johnson & Johnson to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference

May 10, 2023

Johnson & Johnson will participate in the Goldman Sachs 44th Annual Global Healthcare Conference on Tuesday, June 13th, at the Waldorf Astoria Monarch Beach Resort & Club in Dana Point, CA.... | May 10, 2023

Biljana Naumovic Peter Lebowitz Goldman Sachs Annual Global Healthcare Conference Waldorf Astoria Monarch Beach Resort Dana Point

Source: marketscreener.com

Johnson & Johnson : Janssen Marks First Approval Worldwide for AKEEGA® (Niraparib and Abiraterone Acetate Dual Action Tablet) with EC Authorization for the Treatment of Patients with Metastatic Castration Resistant Prostate Cancer with BRCA1/2 Mutations

April 21, 2023

BEERSE, Belgium, 21 April 2023 - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission has granted marketing authorisation for AKEEGA®... | April 21, 2023

Region Flamande United Kingdom City Of Janssen Cilag Gmb Martin Vogel Magda Palhota

Source: marketscreener.com

Johnson & Johnson : Janssen Marks First Approval Worldwide for AKEEGA® (Niraparib and Abiraterone Acetate Dual Action Tablet) with EC Authorisation for the Treatment of Patients with Metastatic Castration Resistant Prostate Cancer with BRCA1/2 Mutations

April 21, 2023

News Release Media Enquiries: Magda Palhota Phone: +351 91 2799282 Email: mpalhota@its.jnj.com ... | April 21, 2023

United Kingdom Region Flamande City Of Janssen Cilag Gmb Peter Lebowitz Martin Vogel

Source: marketscreener.com

NDA Submitted for Niraparib Plus Abiraterone Acetate + Prednisone for Prostate Cancer

March 17, 2023

The NDA for niraparib plus abiraterone acetate and prednisone has been submitted to the FDA for patients with BRCA-positive mCRPC.

Peter Lebowitz Drug Administration Janssen Research Development Janssen Pharmaceutical Companies Of Johnson New Drug Application Global Therapeutic Area Head

Source: oncologynurseadvisor.com

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

NDA Submitted for Niraparib Plus Abiraterone Acetate + Prednisone for Prostate Cancer

March 2, 2023

The NDA for niraparib plus abiraterone acetate and prednisone has been submitted to the FDA for patients with BRCA-positive mCRPC.

Peter Lebowitz Drug Administration Janssen Research Development New Drug Application Global Therapeutic Area Head Janssen Research

Source: empr.com

Janssen submits marketing application for talquetamab

January 5, 2023

European Medicines Agency will consider therapy for the treatment of patients with multiple myeloma - News - PharmaTimes

United States Peter Lebowitz Edmond Chan Janssen Research Janssen Pharmaceutical Companies Of Johnson American Society Of Hematology Annual Meeting

Source: pharmatimes.com

Janssen submits MAA to European Medicines Agency for talquetamab

January 4, 2023

The Janssen Pharmaceutical Companies of Johnson & Johnson has submitted a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for talquetamab to treat patients suffering with relapsed or refractory multiple myeloma (RRMM).

Peter Lebowitz Edmond Chan Janssen Research Development Global Therapeutic Area Drug Administration Cilag Limited Development Global Therapeutic Area

Source: pharmaceutical-business-review.com

Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Talquetamab for the Treatment of Patients wi

January 4, 2023

Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Talquetamab for the Treatment of Patients with Relapsed or Refractory Multiple MyelomaBEERSE, BELGIUM, 3 January 2023 &ndash; The Janssen Pharmaceutical Companies of Johnson &amp; Johnson today announced the subm...

United States Region Flamande Peter Lebowitz Edmond Chan American Society Of Hematology European Medicines Agency Seeking Approval Of Talquetamab

Source: pharmiweb.com